Making an impact on mortality in rheumatoid arthritis: Targeting cardiovascular comorbidity

Boers, Maarten; Dijkmans, Ben A. C.; Gabriel, Sherine E.; Kremers, Hilal Maradit; O'Dell, James Robert; Pincus, Theodore

doi:10.1002/art.20306

Cited by 101 publications

(77 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients with inflammatory diseases such as RA and systemic lupus erythematosus have lower HDL and apolipoprotein A-I (apoA-I) and higher apoB, total cholesterol/HDL-cholesterol ratio, and lipoprotein [a] plasma concentrations (7,24,25). Consequently, they have more atherosclerotic lesions, impaired endothelial function, and increased carotid intima media thickness, which is associated with a higher mortality attributable to cardiovascular diseases than in the general population (24,26,27). In addition, it was recently found that especially RA patients show an impairment of glucose handling and an enhanced insulin response after intravenous glucose loading (8).…”

Section: Intermediary Metabolism: Acute Versus Chronic Inflammatory Smentioning

confidence: 99%

The role of TNF-α in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk

Popa

Netea

Riel

et al. 2007

Journal of Lipid Research

641

412

View full text Add to dashboard Cite

The recent insight that inflammation contributes to the development of atherosclerosis and type 2 diabetes mellitus constitutes a major breakthrough in understanding the mechanisms underlying these conditions. In addition, it opens the way for new therapeutic approaches that might eventually decrease the prevalence of these public health problems. Tumor necrosis factor-a (TNF-a) has been shown to play a key role in these processes and thus might be a potential therapeutic target. Increased concentrations of TNF-a are found in acute and chronic inflammatory conditions (e.g., trauma, sepsis, infection, rheumatoid arthritis), in which a shift toward a proatherogenic lipid profile and impaired glucose tolerance occurs. Although therapeutic blockade of TNF-a worsens the prognosis in patients with abscesses and granulomatous infections, this strategy is highly beneficial in the case of chronic inflammatory conditions, including rheumatoid arthritis.Current investigations assessing the impact of anti-TNF agents on intermediary metabolism suggest that TNF-a blockade may improve insulin resistance and lipid profiles in patients with chronic inflammatory diseases.-Popa, C., M. G. Netea, P. L. C. M. van Riel, J. W. M. van der Meer, and A. F. H. Stalenhoef. The role of TNF-a in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J. Lipid Res. 2007. 48: 751-762.

show abstract

Section: Intermediary Metabolism: Acute Versus Chronic Inflammatory Smentioning

confidence: 99%

The role of TNF-α in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk

Popa

Netea

Riel

et al. 2007

Journal of Lipid Research

641

412

View full text Add to dashboard Cite

show abstract

“…[45][46][47][48] For example, a 50-year-old woman with RA is expected to live for 4 years less than a 50-year-old woman without RA. 49 Patients with RA have a significantly increased risk of ischaemic heart disease.…”

Section: Prognosismentioning

confidence: 99%

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation

Malottki

Barton²,

Tsourapas³

et al. 2011

Health Technol Assess

229

150

View full text Add to dashboard Cite

An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue. How to order:-fax (with credit card details) -post (with credit card details or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you to either print out your order or download a blank order form. Contact details are as follows:Synergie UK (HTA Department) Digital House, The Loddon Centre Wade Road Basingstoke Hants RG24 8QW Email: orders@hta.ac.uk Tel: 0845 812 4000 -ask for 'HTA Payment Services' (out-of-hours answer-phone service) Fax: 0845 812 4001 -put 'HTA Order' on the fax header Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address.Paying by credit card You can order using your credit card by phone, fax or post. SubscriptionsNHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40-50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume.How do I get a copy of HTA on DVD?Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.The website also provides information about the HTA programme and lists the membership of the various committees. HTAAdalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation Dr Paresh Jobanputra has participated in several technology assessments/appraisals related to rheumatoid arthritis as the clinical expert of the assessment group. He works as consultant rheumatologist in a large department of rheumatology. His department has taken part in clinical trials of etanercept, adalimumab, rituximab and tocilizumab. The department receives funding for nurses from Schering-Plough Ltd to administer infliximab to patients currently being treated with this drug. Currently he is the chief investigator of a clinical trial comparing adalimumab versus etanercept (ISRCTN95861172). He has, in the past, received support for educational purposes from Wyeth Pharmaceuticals (etanercept), Abbott (adalimumab) and Roche (rituximab). He has also been involved in an advisory board for Roche in relation to tocilizumab and rituximab, and has accept...

show abstract

“…Of note, the main cause of death was cancer (30.3%), while only ϳ4% of patients had cancer as a comorbid condition at initiation of tumor necrosis factor inhibitor (TNFi) treatment. The analyses were adjusted for age, sex, disease duration, and inflammation (Disease Activity Score in 28 joints and erythrocyte sedimentation rate), which are the most common risk factors for cancer in rheumatoid arthritis (RA) patients (particularly for lymphoma) (2). Obviously, this study did not include the new TNF inhibitors golimumab and certolizumab, which have been marketed in Europe since 2010.…”

Section: To the Editormentioning

confidence: 99%

Neoplasms as the Leading Cause of Death Among Patients With Rheumatoid Arthritis Receiving Tumor Necrosis Factor Inhibitors: Comment on the Article by Simard et al

Yazıcı

Tascilar

Yazıcı

2013

Arthritis & Rheumatism

View full text Add to dashboard Cite

Making an impact on mortality in rheumatoid arthritis: Targeting cardiovascular comorbidity

Cited by 101 publications

References 53 publications

The role of TNF-α in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk

The role of TNF-α in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation

Neoplasms as the Leading Cause of Death Among Patients With Rheumatoid Arthritis Receiving Tumor Necrosis Factor Inhibitors: Comment on the Article by Simard et al

Contact Info

Product

Resources

About